ARTICLE | Clinical News
Cell Pathways starts CP461 Phase IIa
August 6, 2001 7:00 AM UTC
CLPA began Phase IIa testing of its CP461 as a single agent in chronic lymphocytic leukemia, renal cell carcinoma and hormone-refractory prostate cancer. Each study will measure tumor reduction in 14-...